As­traZeneca's big CKD promis­es come to fruition as Farx­i­ga wins ap­proval in pa­tients re­gard­less of di­a­betes sta­tus

Al­most a year af­ter nab­bing a ground­break­ing ap­proval for heart fail­ure pa­tients with or with­out type 2 di­a­betes, As­traZeneca’s Farx­i­ga claimed an­oth­er no­table OK on Fri­day.

The SGLT2 in­hibitor got the FDA green light for chron­ic kid­ney dis­ease in adults at risk of pro­gres­sion, the British phar­ma said late Fri­day af­ter­noon. Much like the heart fail­ure ap­proval, Fri­day’s win is al­so in­di­cat­ed for pa­tients re­gard­less of if they have type 2 di­a­betes. Farx­i­ga was orig­i­nal­ly ap­proved to treat type 2 di­a­betes back in 2014.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER